Market open
Iovance Biotherapeutics/$IOVA
Iovance Biotherapeutics shares are trading lower following multiple law firms filing class action lawsuits against the company for alleged securities fraud.
19 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
838
ISIN
US4622601007
Website
IOVA Metrics
BasicAdvanced
$588M
-
-$1.23
1.06
-
Price and volume
Market cap
$588M
Beta
1.06
52-week high
$12.50
52-week low
$1.65
Average daily volume
16M
Financial strength
Current ratio
4.178
Quick ratio
3.51
Long term debt to equity
5.759
Total debt to equity
6.996
Management effectiveness
Return on assets (TTM)
-27.14%
Return on equity (TTM)
-51.85%
Valuation
Price to revenue (TTM)
2.516
Price to book
0.77
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-1.54
Growth
Revenue change (TTM)
11,070.12%
Earnings per share change (TTM)
-31.83%
3-year earnings per share growth (CAGR)
-18.73%
What the Analysts think about IOVA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
IOVA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IOVA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IOVA News
AllArticlesVideos
Join Class Action to Recover Losses from Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Accesswire·23 minutes ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out
Accesswire·33 minutes ago
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Accesswire·1 hour ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $588M as of May 16, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of May 16, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.